Positioning therapy for Crohn's disease

被引:0
|
作者
Gutierrez A. [1 ,2 ]
Dassopoulos T. [1 ,2 ]
机构
[1] Section of Gastroenterology and Hepatology, Department of Medicine, Washington University in St. Louis, St. Louis, MO
[2] Gastroenterology Division, Washington University School of Medicine, St. Louis, MO 63110, 660 S. Euclid Avenue
关键词
Anti-TNF antibodies; Crohn's disease; Immunomodulators;
D O I
10.1007/s11894-014-0384-2
中图分类号
学科分类号
摘要
The therapy of Crohn's disease is constantly evolving. It is widely recognized that clinical assessment does not stage disease activity accurately and that endoscopic healing is associated with improved long-term outcomes. Disease management is therefore transitioning to a new paradigm that includes direct assessment of disease severity (endoscopically in most patients), followed by assessment of mucosal healing. New approaches have helped optimize the use of the thiopurines, methotrexate and anti-TNF agents. Novel agents with different mechanisms of action are expanding our therapeutic armamentarium. The major challenge of the future will be to identify patient subgroups best suited to particular therapeutic approaches. In the meantime, studies of comparative effectiveness will be crucial in positioning therapies relative to each other. © Springer Science+Business Media 2014.
引用
收藏
相关论文
共 50 条
  • [21] Drug safety in Crohn's disease therapy
    Juillerat, Pascal
    Pittet, Valerie
    Felley, Christian
    Mottet, Christian
    Froehlich, Florian
    Vader, John-Paul
    Gonvers, Jean-Jacques
    Michetti, Pierre
    DIGESTION, 2007, 76 (02) : 161 - 168
  • [22] Cell Therapy of Refractory Crohn’s Disease
    O. V. Knyazev
    A. I. Parfenov
    P. L. Shcherbakov
    I. N. Ruchkina
    A. G. Konoplyannikov
    Bulletin of Experimental Biology and Medicine, 2013, 156 : 139 - 145
  • [23] Nutritional therapy for Crohn's disease in Japan
    Matsui, T
    Sakurai, T
    Yao, T
    JOURNAL OF GASTROENTEROLOGY, 2005, 40 (Suppl 16) : 25 - 31
  • [24] Infliximab therapy for pediatric Crohn's disease
    Veres, Gabor
    Baldassano, Robert N.
    Mamula, Petar
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (12) : 1869 - 1880
  • [25] Overview of biologic therapy for Crohn's disease
    Dryden, Gerald W., Jr.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (08) : 967 - 974
  • [26] Antibiotic therapy for Crohn's disease: A review
    Lal, Simon
    Steinhart, A. Hillary
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 20 (10) : 651 - 655
  • [27] Perianal Crohn's disease and infliximab therapy
    McNamara, DA
    Brophy, S
    Hyland, JMP
    SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND, 2004, 2 (05): : 258 - 263
  • [28] Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm
    D'Amico, Ferdinando
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (SUPPL 2) : II30 - II41
  • [29] Medical Therapy of Fibrostenotic Crohn's Disease
    Siegmund, Britta
    VISZERALMEDIZIN, 2015, 31 (04): : 259 - 264
  • [30] Medical therapy for Crohn's disease strictures
    Van Assche, G
    Geboes, K
    Rutgeerts, P
    INFLAMMATORY BOWEL DISEASES, 2004, 10 (01) : 55 - 60